NLS Pharmaceutics ( (NLSP) ) has released a notification of late filing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NLS Pharmaceutics, a pharmaceutical company based in Zurich, Switzerland, has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing efforts to finalize a merger with Kadimastem Ltd. and the recent financial activities, including raising up to $3 million and securing a $25 million equity facility agreement. Despite these challenges, the company expects to file the report within the 15-day extension period allowed by regulations. There are no anticipated significant changes in financial results from the previous year. NLS Pharmaceutics is committed to completing the filing promptly, as stated by CEO Alexander Zwyer, who signed the notification.
More about NLS Pharmaceutics
YTD Price Performance: -32.48%
Average Trading Volume: 945,805
Technical Sentiment Signal: Buy
Current Market Cap: $3.64M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.